Compare BW & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BW | XERS |
|---|---|---|
| Founded | 1867 | 2005 |
| Country | United States | United States |
| Employees | N/A | 435 |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2015 | 2021 |
| Metric | BW | XERS |
|---|---|---|
| Price | $82.90 | $8.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $8.00 | ★ $10.83 |
| AVG Volume (30 Days) | ★ 4.8M | 1.6M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 41.46 | ★ 100.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,062,388,000.00 | $49,590,000.00 |
| Revenue This Year | $41.58 | $34.37 |
| Revenue Next Year | $66.70 | $22.86 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $1.65 | $5.25 |
| 52 Week High | $22.03 | $10.08 |
| Indicator | BW | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 36.98 | 57.71 |
| Support Level | $7.98 | $6.97 |
| Resistance Level | $11.79 | $9.01 |
| Average True Range (ATR) | 0.93 | 0.36 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 7.32 | 83.76 |
Babcock & Wilcox Enterprises Inc is an energy technologies provider offering energy and emissions control solutions to a broad range of industrial, electrical utility, municipal, and other customers. It offers technologies that utilize coal, natural gas, hydrogen, waste, and biomass to produce energy, environmental solutions, and carbon capture systems. The company's product portfolio comprises steam generation systems, environmental solutions, combustion and fuel systems, and related equipment and services. Additionally, it offers specialized technologies (BrightLoop) in industrial energy production, including hydrogen and syngas. Geographically, the company generates maximum revenue from the United States, and the rest from Canada, the UK, Indonesia, the Philippines, and other markets.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.